

Temperature-Modulated Photodynamic Therapy for the Treatment of Actinic Keratosis on the Extremities: A Pilot Study

ANDREA WILLEY, MD,*[†] R. ROX ANDERSON, MD,^{‡§} AND FERNANDA H. SAKAMOTO, MD, PhD^{‡§}

BACKGROUND The efficacy of photodynamic therapy (PDT) using topical 5-aminolevulinic acid (ALA) for the treatment of actinic keratosis (AKs) is lower on the distal extremities compared with the head and neck areas. The strong temperature dependence of porphyrin synthesis in biologic tissue suggests that heating skin during incubation may improve the efficacy of PDT, particularly in areas where biologic temperatures are naturally lower. The aim of this study was to evaluate the efficacy and tolerability of temperature-modulated PDT for the treatment of AKs on the extremities.

METHODS In this IRB-approved, single-center study, the upper or lower extremities of 20 subjects were treated with 20% ALA under occlusion, followed by 10 J/cm², 417-nm blue light. One of the 2 extremities treated was heated during the 1-hour incubation. Outcome measures included lesion counts, tolerability, and global improvement at baseline, 1 week, and 2 and 6 months after treatment.

RESULTS The median temperatures of the heated and control sides were 38.8°C and 29.4°C, respectively. The median clearance for the heated side was significantly greater than the control side at 2 and 6 months ($p < .0001$). Typical PDT side effects were greater on the heated side compared with the control yet were well tolerated by all subjects.

CONCLUSION Warming the skin during incubation of ALA seems to improve the efficacy of PDT in the treatment of AKs on the extremities and is well tolerated when heat application is controlled within the limits of safety.

The efficacy of cutaneous photodynamic therapy (PDT) using topical 5-aminolevulinic acid (ALA) in the treatment of AK has been demonstrated in a large number of clinical trials.^{1–10} Emerging literature supporting long-term response rates underscores the potential benefits of PDT in the management of nonmelanoma skin cancer.^{11–17} Photodynamic therapy is particularly advantageous for the treatment of large surface areas and is especially suitable for the treatment of multiple actinic keratoses (AKs) and areas of field cancerization.^{18,19} Published studies have demonstrated high clearance rates with multiple topical PDT

regimens that are comparable with other topical therapies used for the treatment of AKs, particularly on the face and scalp.^{8,9,20} However, the efficacy of PDT on the extremities is greatly reduced.^{1,2,10,21,22} The strong relationship between temperature and porphyrin synthesis in biologic tissue^{23–28} suggests that increasing the temperature of the skin during the incubation of ALA may improve the efficacy of PDT, particularly for areas that are naturally lower in temperature such as the distal extremities. 5-aminolevulinic acid is a precursor drug, whereas its metabolite, protoporphyrin IX (PpIX), is the active

*Andrea Willey, MD, PMC, Surgical & Aesthetic Dermatology, Sacramento, California; [†]Department of Dermatology, University of California Davis, Sacramento, California; [‡]Department of Dermatology, Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts; [§]Department of Dermatology, Harvard Medical School, Boston, Massachusetts

A. Willey's employer received a research grant, equipment loan, and study drug from DUSA Pharmaceuticals, Inc. A. Willey is a member of the scientific advisory board for DUSA pharmaceuticals. The other authors have indicated no significant interest with commercial supporters.

© 2014 by the American Society for Dermatologic Surgery, Inc. • Published by Lippincott Williams & Wilkins •
ISSN: 1076-0512 • Dermatol Surg 2014;40:1094–1102 • DOI: 10.1097/01.DSS.0000452662.69539.57

Biofrontera Exhibit 1013
Biofrontera Inc. et al. v. DUSA Pharmaceuticals, Inc.
IPR2022-00056

photosensitizer. Like many metabolic pathways in the body, the conversion of ALA can be modulated by temperature. The aim of this study was to evaluate the efficacy and tolerability of temperature-modulated PDT for the treatment of AKs on the distal extremities.

Methods

Preliminary Determination of Skin Temperature Exposed to Heating Pad in a Single Individual

The temperature of lower extremity skin on a healthy individual with normal vascular tone was measured by a single investigator (A.W.) during a 1-hour exposure to a typical heating pad to determine the appropriate control setting for use during the incubation of ALA. The ambient temperature was recorded as measured with an Acurite temperature monitor (Model 00325; Chaney Instrument Co., Lake Geneva, WI) that measures a range of 0°C to 50°C at 16% to 99% of relative humidity. The skin surface temperature was measured with a calibrated digital thermocouple meter (Traceable model 4233CP; Cole-Parmer, Vernon Hills, IL) with a Type K probe measuring a range of -50°C to 750°C with an accuracy of $\pm 1^\circ\text{C}$ between 0°C and 500°C. The thermocouple probe was taped to the anterior surface of the low leg, which was then wrapped with clear plastic wrap (Saran; SC Johnson, Racine, WI). The extremity was heated by applying a covered Underwriters Laboratories (UL)-tested heating pad (Sunbeam with UltraHeat Technology; Jarden Consumer Solution, Boca Raton, FL). The skin temperature was measured at 1-minute intervals for a duration of 1 hour for each control setting of “low,” “medium,” and “high.” The skin was allowed to return to baseline temperature before measurement at each setting.

The ambient temperature measured 20°C and 65% of relative humidity. The baseline skin temperature of the extremity measured 32°C. When the heat pad was set on “low,” the skin measured 35°C at 1 minute and reached a maximum of 38°C at 15 minutes. At a setting of “medium,” the skin measured 36°C at 1 minute and a maximum of 39°C at 14 minutes. At a setting of “high,” the skin measured 37°C at 1 minute

and a maximum of 42°C at 14 minutes. Subjectively, the heating pad was tolerated well on “low” and “medium”; however, it became uncomfortably warm after a few minutes when set on “high,” which correlated at a temperature of 40°C. Based on these findings, the setting of “medium” was chosen as for the study in clinical subjects.

Enrolment Criteria

Subjects older than 18 years with at least 10 AK lesions on their arms or legs were enrolled in this IRB-approved, single-center study, conducted by a single investigator (A.W.) at a single center in Fairfield, California. Informed consent was obtained in compliance with the ethical guidelines of the 1975 Declaration of Helsinki and HIPPA regulations.^{29,30} Actinic keratosis lesion areas must not have been treated for at least 1 year before enrolment. Subjects were excluded if they met the following criteria during the study period: pregnancy, known history of photosensitivity, sensitivity to ALA or vehicle components, tanning bed exposure, treatment with systemic immunosuppressant, or retinoid medications.

Treatment Protocol

Areas to be treated were swabbed with acetone and gauze and allowed to dry. Topical 20% 5-ALA (Levulan Kerastick; Dusa Pharmaceuticals, Inc., Wilmington, MA) was applied to the entire forearm skin and occluded with plastic wrap (Saran; SC Johnson). One stick (1.5 mL) was used to cover each distal extremity. A covered UL-tested heating pad (Sunbeam with UltraHeat Technology; Jarden Consumer Solution, Boca Raton, FL) set at “medium” was wrapped around 1 randomly selected extremity (right or left) (Figure 1) during the 1-hour incubation. The contralateral extremity (control) was prepared in the same manner, wrapped in plastic, and incubated at room temperature. Control and preheated extremities were randomly assigned by alternating sides at the time of enrolment. After 1 hour, both of the treated sites (heated and control) were irradiated with 10 J/cm² blue light (BLU-U; Dusa Pharmaceuticals, Inc.) for 1,000 seconds with the light positioned 2 to 4 inches from the skin surface. During light irradiation, the treated areas were cooled by a small portable fan set on a mayo




Figure 1. (A) Right arm of Subject 3 at baseline. (B) Left arm of Subject 3 at baseline. (C) Right arm of Subject 3 one week after PDT (heated). Note the increased PDT reaction on heated side compared with control at 1 week, despite similar baseline lesion counts. (D) Left arm of Subject 3 one week after PDT (control).

stand for comfort. The skin temperature was measured through the plastic wrap at baseline and at 15-minute intervals throughout the incubation period (by quickly lifting up the heating pad and replacing it) using an infrared noncontact thermometer (Raytek Minitemp MT4; Fluke Corporation, Everett, WA) that measures temperatures between -18°C and 275°C with an accuracy of $\pm 2^{\circ}\text{C}$ at ambient temperatures of 0°C and 50°C . Lesions were counted at baseline and at 2 and 6 months after treatment by a single investigator (A.W.). Significant differences in lesion counts were determined by Friedman test and the Wilcoxon signed-rank test using $p = .05$ as the cutoff level.

Standardized photographs of each extremity were taken with a high-resolution digital SLR camera (EOS 5D Mark II; Canon Inc., Tokyo, Japan) with a 21.1 megapixel CMOS sensor, EF 100 mm $f/2.8$ USM macro lens, and MR-14EX macro ring flash. Global changes in the treatment area were evaluated at baseline, 1 week, and 2 and 6 months by an investigator (F.H.S.) who was blinded to treatment assignments assessing photographs viewed on a 27-inch monitor with $2,560 \times 1,440$ pixels and RGB color mode (iMac; Apple Inc., Cupertino, CA). For quantitative analysis, photographs were analyzed for the measurement of affected area using the WCIF-ImageJ 1.44 software (Wayne Rasband, National Institutes of Health). To increase

the accuracy of photographic analysis, for each image, the treated field was measured and each apparent AK was manually marked by the blinded evaluator (F.H.S.) and measured. Size variations due to slight change in positions of photographs were minimized by collecting a value relative to the treated area. For every photograph, the total area affected was compared with its baseline. Statistical analysis was performed using 2-factor ANOVA to explore the differences in affected area at 1 week, 2 months, and 6 months compared with baseline, and Bonferroni post hoc analysis was used to locate the difference when ANOVA demonstrated a significant interaction. In all evaluations, a significant difference was accepted at a value of $p < .05$.

Adverse effects, including erythema, edema, stinging/burning, blisters/crusting, hyperpigmentation, and hypopigmentation were graded on a scale of 1 to 4 (1 = mild and 4 = severe) and assessed immediately after treatment, 5 minutes, 1 week, 2 months, and 6 months after treatment. At the 6-month follow-up visit, subjects evaluated overall treatment satisfaction and acceptability of treatment time, adverse effects, and duration of adverse effects.

Results

Twenty subjects aged 57 to 90 years (median, 70) were enrolled in this study between June 22, 2010 and June

15, 2011. Subjects included 5 women and 15 men with skin Type II. Areas treated included the low legs of 3 subjects and the forearms and dorsal hands of 24 subjects. All 20 subjects completed the 6-month study.

The temperature of the heated side during the 1-hour incubation period ranged from 36.4°C to 40.6°C (median, 38.8°C). The temperature of the control side (averaged more than the 1-hour incubation period) ranged from 27.7°C to 33.4°C (median, 29.4°C). Throughout the 1 hour incubation period, the heated side increased in temperature on an average of 9.4°C, whereas the control side increased in temperature on an average of 1.4°C.

The median lesion counts and percent differences at baseline and 2 and 6 months are summarized in Table 1. Lesion counts ranged from 6 to 170 on the heated side and 4 to 105 on the control side. The median baseline lesion count on the heated side (29.5) was not significantly different ($p = .9843$) from the median baseline lesion count for the control side (32.0). Compared with baseline, the median lesion counts for both the heated side and the control side was significantly lower at 2 months ($p < .0001$) and at 6 months ($p < .0001$). In comparing the reduction in lesion counts on the heated versus the control side, the median difference from baseline (%) on the heated side was significantly greater than the median difference from baseline (%) on the control side at 2 months ($p < .0001$) and at 6 months ($p < .0001$). The median counts at 2 months and at 6 months did not differ significantly ($p = .5195$), indicating that the

PDT-heated treatment effect persisted throughout the follow-up period. Clinical photographs of a typical subject at baseline, 1 week, and 6 months are presented in Figures 1 and 2.

Blinded evaluation of standardized photographs assessing global changes in treatment effect demonstrated a significant difference in the area affected by treatment on the heated side compared with the control side, consistent with an increased PDT reaction on the heated side at 1 week compared with baseline. The global differences in the area affected by treatment in the heated versus control side were significant at 2 months when compared with baseline but not at 6 months.

Adverse Effects

The treatment was well tolerated by all subjects. Adverse effects of the heated and control sides were graded on a scale of 1 to 4 (1 = mild and 4 = severe). Median scores at baseline compared with scores at 0 minutes, 5 minutes, and 1 week after treatment are shown in Table 2.

Significant differences in erythema and stinging/burning were seen on the heated versus control side 5 minutes after PDT ($p = .0107$ and $.0039$, respectively). At 1 week after PDT, significant differences were seen in erythema and oozing/crusting ($p = .0010$ and $.0039$, respectively). There were no significant differences in dyspigmentation, scaling, or edema between the heated and control side at any time point.

TABLE 1. Median Lesion Counts and Percent Differences From Baseline at 2 Months and 6 Months

Median Lesion Counts*						†Percent Difference‡			
Heated			Control			2 Months		6 Months	
Baseline	2 Months	6 Months	Baseline	2 Months	6 Months	Heated	Control	Heated	Control
§29.5 (26.8)	§4.0 (5.0)	§4.0 (3.6)	§32.0 (35.0)	§9.5 (10.3)	§7.5 (9.6)	§88.0 (14.8)	§70.5 (28.9)	§88.0 (12.8)	§67.5 (28.8)
$p < .0001$			$p < .0001$			$p < .0001$		$p < .0001$	

*Friedman test.

† $[(\text{Baseline count} - \text{2-month or 6-month count})/\text{baseline count}] \times (100)$.

‡Wilcoxon signed-rank test.

§Median (IQR); IQR, interquartile range, a measure of dispersion; IQR = 75th percentile – 25th percentile.



Figure 2. (A) Right arm of Subject 3 six months after PDT (heated). Note increased clearance of AKs on the heated side compared with control. (B) Left arm of Subject 3 six months after PDT (control). Note early recurrence of AK lesions.

The median subject satisfaction score at 6 months was slightly higher in the control side (2 vs 1), but the difference did not achieve significance ($p = .0781$). Treatment time was acceptable to all 20 subjects who responded. When asked if adverse effects and side effects were acceptable, 18 subjects agreed totally, 1 subject agreed a little, and 1 subject neither agreed nor disagreed. Duration of side effects was acceptable to 18 subjects (totally agree), whereas 2 subjects agreed a little.

One subject developed significant erythema and blisters on both arms (score of 4 on the heated side and 3 on the control side). The blisters resolved with the use of emollients for 2 weeks after treatment. Lesion clearance was near complete at 2 and 6 months after treatment. This subject graded the overall satisfaction with treatment as “excellent,” and graded acceptability of side effects as “neither acceptable nor unacceptable” (neutral), and the duration of side effects and the time required for treatment as “totally

acceptable.” Review of the medical history revealed a long history of iron deficiency, thyroid disease, hypertension, and arthritis. Medications included levothyroxine, hydrochlorothiazide, and diclofenac, which were started 4 days before PDT.

Another subject demonstrated a marked reduction in hair (more prominent on the heated side) 1 week after treatment, which regrew by the 2-month follow-up visit. Although not prospectively evaluated nor graded, subtle reversible hair loss was also noted in the photographs of other subjects.

Discussion

It is no surprise that the synthesis of porphyrins in the heme biosynthetic pathway is a temperature-dependent process. Indeed, biologic processes are highly temperature dependent, with enzymes functioning at ideal temperatures that govern the rate at which chemical reactions occur to support the “biochemistry of life.” In general, for a 10°C change in temperature, the metabolic rate in the human body will change by a factor of 2 to 3, increasing with elevated temperatures and decreasing at lowered temperatures. Yet, the strong temperature dependence of porphyrin production and its clinical relevance has only recently been recognized.^{23–28}

In 1999, using fluorescence spectroscopy, Moan and colleagues demonstrated that the production of protoporphyrin IX (PpIX) increased nearly twofold when the temperature of normal murine skin in vivo was increased from 37°C to 42°C after a 3-hour incubation of 20% ALA and was increased fourfold after a 6-hour incubation.²³ Although PpIX concentration peaked after 3 hours, the majority of PpIX was produced after 1 to 2 hours. Importantly, no PpIX was produced at 12°C. This group then demonstrated in WiDr cells and in murine skin a twofold to threefold increase in PpIX production at 36°C to 7°C compared with 28°C to 32°C, concluding that conversion of ALA to PpIX is significantly reduced at 30°C.^{23–25} Protoporphyrin IX fluorescence was detectable 6 to 10 minutes after incubation of ALA at 37°C.²⁵ Further study of human forearm skin in vivo demonstrated a 50% increase in PpIX production when the

TABLE 2. Statistical Comparison of Adverse Effects on Heated and Control Sides

Adverse Effect	<i>p</i> Value (Heated vs Control)*					
	Baseline	Immediately After Treatment	5 Minutes After Treatment	1 Week	2 Months	6 Months
Erythema	1.000 [†]	—	.0107 [‡]	.0010 [‡]	.5000 [†]	1.000 [†]
Edema	1.000 [†]	—	.5000 [†]	.5000 [†]	1.000 [†]	1.000 [†]
Stinging/burning	1.000 [†]	.0078 [‡]	.0039 [‡]	.5000 [†]	1.000 [†]	1.000 [†]
Oozing/crusting	1.000 [†]	—	—	.0039 [‡]	1.000 [†]	1.000 [†]
Scaling/dryness	1.000 [†]	—	—	.6250 [†]	1.000 [†]	.7500 [†]
Hyperpigmentation	1.000 [†]	—	—	1.000 [†]	1.000 [†]	1.000 [†]
Hypopigmentation	1.000 [†]	—	—	1.000 [†]	1.000 [†]	1.000 [†]

Scale 1 to 4 in which 1 = mild and 4 = severe.
 *Wilcoxon signed-rank test.
 †Not significant.
 ‡Significant.

temperature was increased from 31°C to 36°C that was significant after 2 hours of incubation.²⁴

Subsequent study by Van den Akker and colleagues²⁷ demonstrated that the penetration of 20% ALA through murine skin in vitro was increased at 37°C compared with 32°C after 1 hour of incubation. Further in vivo study of 6 human subjects' back skin maintained at 15°C, 25°C, 31°C, and 41°C confirmed the increasing fluorescence of PpIX with increasing temperature, with little or no PpIX produced at 15°C. These authors conclude that the increase in PpIX fluorescence is due to the increase in skin penetration and increased cellular uptake and intracellular enzyme activity.

More recently, Yang and colleagues²⁸ studied the influence of temperature from 20°C to 50°C on ALA penetration and PpIX production in keratinocytes in vitro. Cell death increased as temperature increased, with the rate of apoptosis and morphological phototoxic effects increasing with temperatures beyond 38°C in PDT-treated cells. These studies clearly demonstrate that elevating temperature augments photodynamic reactions in keratinocytes in vitro and serve as a foundation for clinical practices using hyperthermia to enhance the effectiveness of PDT.

The skin is a vital thermoregulatory organ of the body, modulating the flow of heat through the insulating

shell and the surrounding environment through complex mechanisms of constriction and dilation of cutaneous blood vessels under sympathetic and adrenergic control.^{31,32} Core body temperatures are maintained in the fairly narrow range of 37.2°C to 37.7°C³³ in young healthy adults despite highly variable ambient conditions. Skin temperature, averaged throughout the body surface, is typically 6°C to 7°C below that of the body's core.^{34,35} Under normal resting conditions, temperatures of the skin range from 27.5°C to 35.5°C depending on the location, with the lowest temperatures on the distal extremities and the highest on the head and trunk areas.³⁶ Tonic vasoconstriction of cutaneous vessels aimed at minimizing heat loss leads to cooling of the skin and reduced metabolic activity at typical domestic room temperatures of 24°C to 28°C.^{37,38} Ambient temperatures of 20°C are typical for most offices, however, vary greatly throughout the day, in different rooms, geographic regions, and seasons (OSHA recommends 20–24.4°C for offices, cooler for hospital settings).³⁹ The temperature of human skin uniquely varies parabolically with changes in ambient temperatures through highly responsive reflex control of vascular tone.³¹ Local warming of the skin causes a direct and substantial vasodilation in the area being warmed,³⁸ with maximal dilation at 42°C in young healthy persons.³² Thus, human skin is highly sensitive and readily responsive to changes in local temperature within

a range that is relevant to porphyrin synthesis and is likely highly relevant to the efficacy of cutaneous PDT under ordinary circumstances, even in the absence of adjunctive skin warming.

Fundamentally, PDT depends on 3 components: an active photosensitizer, oxygen, and light (energy). The effects of heat-induced vasodilation might also result in an increase of oxygen biodistribution, contributing to a higher PDT effect.

Importantly, the same thermoregulatory processes in skin that maintain homeostasis also provide vital protection from potential thermal injury.^{34,40} Several studies have tried to determine the threshold of burn injury in skin with local heat exposure.^{41–45} In the most classic study conducted by Moritz and Henriques,⁴¹ it was determined that a continuous contact for 8 hours at 43°C was required to create a burn on the forearm skin of healthy volunteers. Others have similarly concluded that 43°C is the safe limit for prolonged exposure to a hot object in healthy well-perfused skin.^{42,43} Diller⁴⁴ further calculated that 3 to 28 hours of exposure to a heating pad at 40°C would be required for a first-degree burn. Importantly, the threshold for thermal injury has not been determined for thin or poorly perfused skin.⁴²

Although heating pads are generally considered safe when used appropriately by individuals with normal functioning vasomotor and neurosensory function, the need for caution should be appreciated, especially for those who may be more susceptible to thermal injury.^{32,40,46–51} The use of heating pads is contraindicated in persons who have a reduced sensitivity to heat or impaired sensory and vasomotor function, including patients with diabetes, peripheral vascular disease, or any condition of sensory loss.^{40,46–51} Heating pads that have been tested by UL ensure engineering standards and safety testing and should be used in accordance with detailed warning labels.⁴⁴ Specifically, practices of prolonged use, local compression, or lack of insulating covering should be strictly avoided.

This study demonstrates that moderately increasing the skin temperature during the incubation of ALA enhances the PDT reaction in skin and increases the efficacy of AK

clearance on the distal extremities after a single treatment to a level that is similar to published data for the head and facial skin.^{8,9,20} Warming the skin within the threshold of thermal tolerability was well tolerated by subjects, despite moderate increases in stinging during light exposure and increased PDT skin reactions after treatment. A long-term follow-up study is currently underway to evaluate the longevity of AK clearance. The results of this study suggest that the potential for local skin warming to enhance cutaneous PDT for other indications may also be promising. At the least, these data should bring awareness to the clinical relevance of ambient temperatures during the incubation of porphyrins used for cutaneous PDT for all indications.

Limitations

The temperatures reported are likely slightly lower than the actual skin temperature because of the rapid loss of heat when the heating pad is lifted to obtain the reading and are limited by the precision of the infrared thermometer ($\pm 2^\circ\text{C}$). The reliability of infrared thermometers for the measurement of skin temperatures has been demonstrated.^{52,53} However, because of heat dissipation during temperature measurement and the potential interference of the plastic wrap, the use of a thermocouple applied directly to the skin surface under the plastic wrap and heat pad is recommended for greater accuracy in future studies.

Blinded photographic analysis comparing differences in the area of skin affected by visible AKs at 1 week compared with baseline was consistent with an increased PDT reaction on the heated side compared with controls. When comparing baseline photographs with 2 and 6 months, global differences were significant only at the 2-month time point. However, the decrease in lesion counts remained significant throughout the study period. This finding is likely due to the inadequate sensitivity of the global assessment analysis in subjects with low numbers of AK lesions, which affect a small area compared with the entire treatment area.

References

1. Fink-Puches R, Hofer A, Smolle J, Kerl H, et al. Primary clinical response and long-term follow-up of solar keratoses treated with topically applied 5-aminolevulinic acid and irradiation by different wave bands of light. *J Photochem Photobiol B* 1997;41:145–51.

2. Jeffes EW, McCullough JL, Weinstein GD, Kaplan R, et al. Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. *J Am Acad Dermatol* 2001;45:96–104.
3. Piacquadio DJ, Chen DM, Farber HF, Fowler JF Jr, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. *Arch Dermatol* 2004;140:41–6.
4. Tschen EH, Wong DS, Pariser DM, Dunlap FE, et al; Phase IV ALA-PDT Actinic Keratosis Study Group. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. *Br J Dermatol* 2006;155:1262–9.
5. Moloney FJ, Collins P. Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis. *Br J Dermatol* 2007;157:87–91.
6. Piaserico S, Belloni Fortina A, Rigotti P, Rossi B, et al. Topical photodynamic therapy of actinic keratosis in renal transplant recipients. *Transplant Proc* 2007;39:1847–50.
7. Stritt A, Merk HF, Braathen LR, Felbert V. Photodynamic therapy in the treatment of actinic keratosis. *Photochem Photobiol* 2008;84:388–98.
8. Smith S, Piacquadio D, Morhenn V, Atkin D, et al. Short incubation PDT versus 5-FU in treating actinic keratoses. *J Drugs Dermatol* 2003;2: 629–35.
9. Sotiriou E, Apalla Z, Maliamani F, Zappas N, et al. Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities. *J Eur Acad Dermatol Venereol* 2009;23:1061–5.
10. Taub AF, Garretson CB. A randomized, blinded, bilateral intraindividual vehicle-controlled trial of the use of photodynamic therapy with 5-aminolevulinic acid and blue light for the treatment of actinic keratoses of the upper extremities. *J Drugs Dermatol* 2011;10: 1049–56.
11. Apalla Z, Sotiriou E, Chovarda E, Lefaki I, et al. Skin Cancer: preventative photodynamic therapy in patients with face and scalp cancerization. A randomized placebo controlled study. *Br J Dermatol* 2010;162:171–5.
12. Goldberg LH, Landau JM, Moody MN, Marquez D, et al. Evaluation of the chemopreventative effects of ALA PDT in patients with multiple actinic keratoses and a history of skin cancer. *J Drugs Dermatol* 2012;11:593–7.
13. Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. *Br J Dermatol* 2008;159:1245–66.
14. Braathen LR, Szeimies RM, Basset-Seguín N, Bissonnette R, et al; International Society for Photodynamic Therapy in Dermatology. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. *International Society for Photodynamic Therapy in Dermatology*, 2005. *J Am Acad Dermatol* 2007;56:125–43.
15. Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. *Acta Derm Venereol* 2006;86:25–8.
16. Wennberg AM, Stenquist B, Stockfleth E, Keohane S, et al. Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study. *Transplantation* 2008;86:423–9.
17. Willey A, Mehta S, Lee PK. Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy. *Dermatol Surg* 2010;36:652–8.
18. Braathen LR, Morton CA, Basset-Seguín N, Bissonnette R, et al. Photodynamic therapy for skin field cancerization: an international consensus. *International Society for Photodynamic Therapy in Dermatology*. *J Eur Acad Dermatol Venereol* 2012;26:1063–6.
19. Zhao B, He YY. Recent advances in the prevention and treatment of skin cancer using photodynamic therapy. *Expert Rev Anticancer Ther* 2010;10:1797–809.
20. Hadley J, Tristani-Firouzi P, Hull C, Florell S, et al. Results of an investigator-initiated single-blind split-face comparison of photodynamic therapy and 5% imiquimod cream for the treatment of actinic keratoses. *Dermatol Surg* 2012;38:722–7.
21. Tyrrell JS, Morton C, Campbell SM, Curnow A. Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites. *Br J Dermatol* 2011;164:1362–8.
22. Lesar A, Ferguson J, Moseley H. An investigation of the fluorescence induced by topical application of 5-aminolaevulinic acid and methyl aminolaevulinate at different body sites on normal human skin. *Photodiagnosis Photodyn Ther* 2011;8:97–103.
23. Juzenas P, Sørensen R, Iani V, Moan J. Uptake of topically applied 5-aminolevulinic acid and production of protoporphyrin IX in normal mouse skin: dependence on skin temperature. *Photochem Photobiol* 1999;69:478–81.
24. Moan J, Berg K, Gadmar OB, Iani V, et al. The temperature dependence of protoporphyrin IX production in cells and tissues. *Photochem and Photobiol* 1999;70:669–73.
25. Juzeniene A, Juzenas P, Kaalhus O, Iani V, et al. Temperature effect on accumulation of protoporphyrin IX after topical application of 5-aminolevulinic acid and its methylester and hexylester derivatives in normal mouse skin. *Photochem Photobiol* 2002;76:452–6.
26. Ishida N, Watanabe D, Mizutani K, Akimoto M, et al. Heating increases protoporphyrin IX production in normal skin after delivery of 5-aminolevulinic acid by iontophoresis. *Photodermatol Photoimmunol Photomed* 2009;25:333–4.
27. Van den Akker JT, Boot K, Vernon DI, Brown SB, et al. Effect of elevating the skin temperature during topical ALA application on in vitro ALA penetration through mouse skin and in vivo PpIX production in human skin. *Photochem Photobiol Sci* 2004;3:263–7.
28. Yang J, Chen AC, Wu Q, Jiang S, et al. The influence of temperature on 5-aminolevulinic acid-based photodynamic reaction in keratinocytes in vitro. *Photodermatol Photoimmunol Photomed* 2010;26:83–8.
29. Flanagan A. Who wrote the declaration of Helsinki? *JAMA* 1997;277: 925–6.
30. WMA's Declaration of Helsinki serves as a guide to physicians. *JAMA* 1964;189:33–4.
31. Rowell LB. Reflex control of the cutaneous vasculature. *J Invest Dermatol* 1977;69:154–66.
32. Johnson JM, Kellogg DL Jr. Local thermal control of the human cutaneous circulation. *J Appl Physiol* 2010;109:1229–38.
33. Mackowiak PA, Wasserman SS, Levine MM. A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. *JAMA* 1992;268:1578–80.
34. Petrofsky J, Alshahmmari F, Yim JE, Hamdan A, et al. The inter-relationship between locally applied heat, ageing and skin blood flow on heat transfer into and from the skin. *J Med Eng Technol* 2011;35:262–74.
35. Griffith JM, Hamilton A, Long G, Mujezinovic A, et al. Human skin temperature response to absorbed thermal power. *SPIE Medical Imaging Symposium: Newport Beach*, 1997; pp. 129–34.
36. Hertzman AB. Some relations between skin temperature and blood flow. *Am J Phys Med* 1953;32:233–51.
37. Hertzman AB. Vasomotor regulation of cutaneous circulation. *Physiol Rev* 1959;39:280–306.
38. Hertzman AB, Randall WC. Regional differences in the basal and maximal rates of blood flow in the skin. *J Appl Physiol* 1948;1:234–41.

39. Standard Number 1910.1000 OSHA Policy on Indoor Air Quality: Office Temperature/Humidity and Environmental Tobacco Smoke. Available from: www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=INTERPRETATIONS&p_id=24602. Accessed on December 8, 2013.
40. Charkoudian N. Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. *Mayo Clin Proc* 2003;78:603–12.
41. Moritz AR, Henriques FC. Studies of Thermal Injury: II. The relative importance of time and surface temperature in the causation of cutaneous burns. *Am J Pathol* 1947;23:695–720.
42. Greenhalgh DG, Lawless MB, Chew BB, Crone WA, et al. Temperature threshold for burn injury: an oximeter safety study. *J Burn Care Rehabil* 2004;25:411–5.
43. Siekmann H. Recommended maximum temperatures for touchable surfaces. *Appl Ergon* 1990;21:69–73.
44. Diller KR. Analysis of burns caused by long-term exposure to a heating pad. *J Burn Care Rehabil* 1991;12:214–7.
45. Suzuki T, Hirayama T, Aihara K, Hirohata Y. Experimental studies of moderate temperature burns. *Burns* 1991;17:443–51.
46. Blatteis CM. Age-dependent changes in temperature regulation—a mini review. *Gerontology* 2012;58:289–95.
47. Bill TJ, Edlich RF, Himel HN. Electric heating pad burns. *J Emerg Med* 1994;12:819–24.
48. Gosselin TK. Thermal wounds following heating pad use. *Clin J Oncol Nurs* 2003;7:87–8.
49. Ozgenel Ege GY, Ozcan M. Heating-pad burn as a complication of abdominoplasty. *Br J Plast Surg* 2003;56:52–3.
50. Stevenson TR, Hammond DC, Keip D, Argenta LC. Heating pad burns in anesthetic skin. *Ann Plast Surg* 1985;15:73–5.
51. Katcher ML, Shapiro MM. Lower extremity burns related to sensory loss in diabetes mellitus. *J Fam Pract* 1987;24:149–51.
52. Kistemaker JA, Den Hartog EA, Daanen HA. Reliability of an infrared forehead skin thermometer for core temperature measurements. *J Med Eng Technol* 2006;30:252–61.
53. Burnham RS, McKinley RS, Vincent DD. Three types of skin-surface thermometers: a comparison of reliability, validity, and responsiveness. *Am J Phys Med Rehabil* 2006;85:553–8.

Address correspondence and reprint requests to: Andrea Willey, MD, 2277 Fair Oaks Boulevard, Suite 402, Sacramento, CA 95825, or e-mail: andrea.willey@mac.com

Home > October 2014 - Volume 40 - Issue 10

< Previous Issue | Next Issue >



October 2014 - Volume 40 - Issue 10

- Table of Contents Outline
- Subscribe to eTOC
- View Contributor Index

Advertisement



Original Articles

Comparison of the Effect of Diode Laser Versus Intense Pulsed Light in Axillary Hair Removal

Ormiga, Patricia; Ishida, Cleide Eiko; Boechat, Alvaro; More

Dermatologic Surgery. 40(10):1061-1069, October 2014.

Abstract Favorites PDF Get Content & Permissions

BUY

Table of Contents Outline | Back to Top

Original Article

The Anatomical Origin and Course of the Angular Artery Regarding Its Clinical Implications

Kim, Yi-Suk; Choi, Da-Yae; Gil, Young-Chun; More

Dermatologic Surgery. 40(10):1070-1076, October 2014.

Abstract Favorites PDF Get Content & Permissions

BUY

To Scoop or Not to Scoop: The Diagnostic and Therapeutic Utility of the Scoop-Shave Biopsy for Pigmented Lesions

Mendese, Gary; Maloney, Mary; Bordeaux, Jeremy

Dermatologic Surgery. 40(10):1077-1083, October 2014.

Abstract Favorites PDF Get Content & Permissions

BUY

Periorbital Mohs Reconstruction: Characterization of Tumor Histology, Anatomic Location, and Factors Influencing Postoperative Complications

Michelotti, Brett; Mathis, Ryan; Roberts, John; More

Dermatologic Surgery. 40(10):1084-1093, October 2014.

Abstract Favorites PDF Get Content & Permissions

BUY

Temperature-Modulated Photodynamic Therapy for the Treatment of Actinic Keratosis on the Extremities: A Pilot Study

Wiley, Andrea; Anderson, R. Rox; Sakamoto, Fernanda H.

Dermatologic Surgery. 40(10):1094-1102, October 2014.

BUY

Skin Sterility After Application of a Vapocoolant Spray

Schleicher, William F.; Richards, Bryson G.; Huettner, Franziska; More

Dermatologic Surgery. 40(10):1103-1107, October 2014.

BUY

Complications Using Intense Ultrasound Therapy to Treat Deep Dermal Facial Skin and Subcutaneous Tissues

Sabet-Peyman, Esfandiar J.; Woodward, Julie A.

Dermatologic Surgery. 40(10):1108-1112, October 2014.

BUY

Safety and Efficacy of Microfocused Ultrasound to Lift, Tighten, and Smooth the Buttocks

Goldberg, David J.; Hornfeldt, Carl S.

Dermatologic Surgery. 40(10):1113-1117, October 2014.

BUY

A Retrospective Review and Observational Study of Outcomes and Safety of Bimatoprost Ophthalmic Solution 0.03% for Treating Eyelash Hypotrichosis

Yoelin, Steven G.; Fagien, Steven; Cox, Sue Ellen; More

Dermatologic Surgery. 40(10):1118-1124, October 2014.

BUY

Hair Transplantation in the Surgical Treatment of Central Centrifugal Cicatricial Alopecia

Callender, Valerie D.; Lawson, Christina N.; Onwudiwe, Oge C.

Dermatologic Surgery. 40(10):1125-1131, October 2014.

BUY

Partial Matricectomy With Curettage and Electrocautery: A Comparison of Two Surgical Methods in the Treatment of Ingrown Toenails

Ozan, Firat; Dogar, Fatih; Altay, Taskin; More

Dermatologic Surgery. 40(10):1132-1139, October 2014.

BUY

[Table of Contents Outline](#) | [Back to Top](#)

Reconstructive Conundrum

Nasal Tip Revision Using a Dermal Graft

Jensen, J. Daniel; Cohen, Joel L.

Dermatologic Surgery. 40(10):1140-1142, October 2014.

BUY

[Table of Contents Outline](#) | [Back to Top](#)

Obituary

On the Shoulders of Giants

Niamtu, Joe III

Dermatologic Surgery. 40(10):1143-1144, October 2014.

☆ Favorites  PDF  Get Content & Permissions

[BUY](#)

[Table of Contents Outline](#) | [Back to Top](#)

Letters and Communications

Use of Hyaluronidase in Patients With Bee Allergy

Keller, Emily Catherine; Kaminer, Michael S.; Dover, Jeffrey S.

Dermatologic Surgery. 40(10):1145-1147, October 2014.

☆ Favorites  PDF  Get Content & Permissions

[BUY](#)

A Mathematical Proof of How the Outgrowth Angle of Hair Follicles Influences the Injury to the Donor Area in FUE Harvesting

Zontos, Georgios; Rose, Paul T.; Nikiforidis, George

Dermatologic Surgery. 40(10):1147-1150, October 2014.

☆ Favorites  PDF  Get Content & Permissions

[BUY](#)

Previous Nail Surgery Is a Risk Factor for Recurrence of Ingrown Nails

Erdogan, Fatma G.; Guven, Munevver; Erdogan, Beyza D.; [More](#)

Dermatologic Surgery. 40(10):1152-1154, October 2014.

☆ Favorites  PDF  Get Content & Permissions

[BUY](#)

In Situ Melanoma of the Nail Unit Presenting as a Rapid Growing Longitudinal Melanonychia in a 9-Year-Old White Boy

Bonamonte, Domenico; Arpaia, Nicola; Cimmino, Antonietta; [More](#)

Dermatologic Surgery. 40(10):1154-1157, October 2014.

☆ Favorites  PDF  Get Content & Permissions

[BUY](#)

Multiple Subungual Squamous Cell Carcinomas in a Patient With Incontinentia Pigmenti

Pena, Zachary G.; Brewer, Jerry D.

Dermatologic Surgery. 40(10):1159-1161, October 2014.

☆ Favorites  PDF  Get Content & Permissions

[BUY](#)

[Table of Contents Outline](#) | [Back to Top](#)

Letters and Communication

Google Glass: Dermatologic and Cosmetic Surgery Applications

Niamtu, Joe III

Dermatologic Surgery. 40(10):1150-1152, October 2014.

☆ Favorites  PDF  Get Content & Permissions

[BUY](#)

Controversies Over Subungual Tumors in Incontinentia Pigmenti

Mahmoud, Bassel H.; Zembowicz, Artur; Fisher, Emily

Dermatologic Surgery. 40(10):1157-1159, October 2014.

☆ Favorites  PDF  Get Content & Permissions

[BUY](#)

[Table of Contents Outline](#) | [Back to Top](#)



Never Miss an Issue

Get new journal Tables of Contents sent right to your email inbox

[Get New Issue Alerts](#)

Browse Journal Content

- Most Popular
- About the Journal
- Current Issue
- Subscribe
- For Authors
- Past Issues
- Register on the website
- Get eTOC Alerts

For Journal Authors

- Submit an article
- How to publish with us

Customer Service

Live Chat

customerservice@lww.com

800-638-3030 (within USA)

301-223-2300 (international)

[Activate Journal Subscription](#)

[Browse the help center](#)



Full Text Access for Subscribers:



Individual Subscribers

Log in for access



Institutional Members

Access on Ovid®

Not a Subscriber?

Buy

Subscribe

Request Permissions →

Article Level Metrics



Tweeted by 1

23 readers on Mendeley

View full article metrics including social shares, article views and publishing history

ORIGINAL ARTICLE



Cite



Share



Favorites



Permissions

Temperature-Modulated Photodynamic Therapy for the Treatment of Actinic Keratosis on the Extremities

A Pilot Study

Willey, Andrea MD^{1,†}; Anderson, R. Rox MD^{2,§}; Sakamoto, Fernanda H. MD, PhD^{2,§}

Author Information 

Dermatologic Surgery: October 2014 - Volume 40 - Issue 10 - p 1094-1102
doi: 10.1097/01.DSS.0000452662.69539.57

BUY

 Metrics

Related Links

- Articles in PubMed by Andrea Willey, MD
- Articles in Google Scholar by Andrea Willey, MD
- Other articles in this journal by Andrea Willey, MD

Advertisement



Abstract

BACKGROUND

The efficacy of photodynamic therapy (PDT) using topical 5-aminolevulinic acid (ALA) for the treatment of actinic keratosis (AKs) is lower on the distal extremities compared with the head and neck areas. The strong temperature dependence of porphyrin synthesis in biologic tissue suggests that heating skin during incubation may improve the efficacy of PDT, particularly in areas where biologic temperatures are naturally lower. The aim of this study was to evaluate the efficacy and tolerability of temperature-modulated PDT for the treatment of AKs on the extremities.

METHODS

In this IRB-approved, single-center study, the upper or lower extremities of 20 subjects were treated with 20% ALA under occlusion, followed by 10 J/cm², 417-nm blue light. One of the 2 extremities treated was heated during the 1-hour incubation. Outcome measures included lesion counts, tolerability, and global improvement at baseline, 1 week, and 2 and 6 months after treatment.

RESULTS

The median temperatures of the heated and control sides were 38.8°C and 29.4°C, respectively. The median clearance for the heated side was significantly greater than the control side at 2 and 6 months ($p < .0001$). Typical PDT side effects were greater on the heated side compared with the control yet were well tolerated by all subjects.

CONCLUSION

Warming the skin during incubation of ALA seems to improve the efficacy of PDT in the treatment of AKs on the extremities and is well tolerated when heat application is controlled within the limits of safety.

© 2014 by the American Society for Dermatologic Surgery, Inc. Published by Lippincott Williams & Wilkins